Tandem Diabetes Care, Inc.NASDAQ: TNDM

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

· Issued by Tandem Diabetes Care, Inc. via Business Wire

Summary by 6ix AI

Tandem Diabetes Care, an insulin delivery and diabetes technology company, reported worldwide sales of $283.7 million for the third quarter ended September 30, 2026, up 14% from $249.3 million a year earlier, and a net loss of $7.1 million compared with $21.2 million.

Key details

  • US sales rose 9% to $191.0 million from $175.6 million, and international sales rose 26% to $92.6 million from $73.6 million (27% in constant currency, meaning at the prior year's exchange rates).
  • Gross margin was 57%, compared with 54%; operating loss was $2.4 million, compared with $22.9 million; net loss per share was $0.10, compared with $0.31.
  • Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding certain items) was $18.0 million, or 6% of sales, compared with $2.8 million, or 1% of sales.
  • Pump shipments were approximately 33,000 worldwide, including nearly 23,000 in the US; 15% of US sales came through the pharmacy channel under its pay-as-you-go reimbursement model.
  • The company reaffirmed 2026 guidance of approximately $1.065 billion to $1.085 billion in sales, gross margin of approximately 56% to 57% and adjusted EBITDA margin of approximately 5% to 6% of sales.

What’s still pending

  • The 2026 sales, margin and adjusted EBITDA margin figures are company estimates for the year ending December 31, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

  • Sales of $283.7 million worldwide, including $191.0 million in the United States (U.S.)
  • Gross margin of 57%, up 270 basis points compared to third quarter 2025
  • Pump shipments of approximately 33,000 worldwide, including nearly 23,000 pumps in the U.S.
  • Operating margin improved 830 basis points compared to third quarter 2025
  • Scaled pay-as-you-go reimbursement model resulting in 15% of U.S. sales through the pharmacy channel

Third Quarter 2026 and Recent Strategic Highlights

  • Increased pharmacy formulary coverage to approximately 50% of U.S. lives
  • Expanded availability of t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor to 11 international markets
  • Announced international availability of Tandem Mobi in 12 countries

“Tandem’s third-quarter performance demonstrates that our strategy is delivering results,” said John Sheridan, president and chief executive officer. “We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.”

Third Quarter 2026 Financial Results Compared to Third Quarter 2025

  • Sales: Worldwide sales increased 14% to $283.7 million, compared to $249.3 million on a reported basis and in constant currency(1).
    Sales in the U.S. increased 9% to $191.0 million, compared to $175.6 million.
    International sales increased 26% to $92.6 million, compared to $73.6 million. International sales increased 27% in constant currency(1).
    Shipments in the U.S. were nearly 23,000 pumps, compared to more than 20,000 pumps.
    International shipments were nearly 11,000 pumps, compared to more than 9,000 pumps.
  • Gross profit: Gross profit was $160.4 million, compared to $134.3 million. Gross margin was 57%, compared to 54%.
  • Operating loss: Operating loss was $2.4 million, or negative 1% of sales, compared to operating loss of $22.9 million, or negative 9% of sales.
  • Net loss: Net loss was $7.1 million, compared to net loss of $21.2 million.
    Adjusted EBITDA(1) was $18.0 million, or 6% of sales, compared to $2.8 million, or 1% of sales.

See tables for additional financial information.

2026 Financial Guidance

For the year ending December 31, 2026, the Company is reaffirming the following financial guidance:

  • Sales are estimated to be approximately $1.065 billion to $1.085 billion
    • U.S. sales of approximately $730 million to $745 million
    • International sales of approximately $335 million to $340 million
  • Gross margin is estimated to be approximately 56% to 57% of sales
  • Adjusted EBITDA margin(2) is estimated to be approximately 5% to 6% of sales
  • Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $85 million. This includes:
    • Approximately $65 million non-cash, stock-based compensation expense
    • Approximately $20 million depreciation and amortization expense

For a comprehensive overview of the Company's guidance assumptions for 2026, including pricing and transition assumptions for the adoption of pay-as-you-go reimbursement in the U.S. and the initiation of international direct operations, please see the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at https://investor.tandemdiabetes.com.

(1)

Constant currency sales growth and adjusted EBITDA are non-GAAP financial measures. See “Non-GAAP Financial Measures” below for additional information on these non-GAAP financial measures. A reconciliation of constant currency to GAAP sales can be found in Table C “Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth” attached to this press release. A reconciliation of adjusted EBITDA to net loss can be found in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

(2)

Adjusted EBITDA margin is a non-GAAP financial measure. The Company has not reconciled adjusted EBITDA margin outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot reasonably be predicted with the level of precision required, the Company is unable to provide outlook for the comparable GAAP measure (net income (loss) as a percentage of sales). Forward-looking estimates of adjusted EBITDA margin are made in a manner consistent with relevant calculations and assumptions noted herein.

Non-GAAP Financial Measures

Certain financial measures presented in this press release are not calculated or presented in accordance with generally accepted accounting principles (GAAP). The Company has provided these non-GAAP financial measures to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company’s management believes these non-GAAP financial measures are important operating performance indicators because they either exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results, or aid in presenting information on a consistent and comparable basis. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, financial measures calculated and presented in accordance with GAAP. To the extent the Company uses such non-GAAP financial measures in the future, the Company expects they will be calculated using a consistent method from period to period and, if not, an explanation will be provided.

Adjusted EBITDA and Adjusted EBITDA Margin

Adjusted EBITDA is a non-GAAP financial measure that is calculated by adding back to net loss the following items: income tax expense (benefit); interest income, interest expense and other, net; depreciation and amortization; litigation and settlement expense; stock-based compensation expense; and non-recurring facility impairment and restructuring costs. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by GAAP sales. A reconciliation of adjusted EBITDA to net loss has been provided in Table D “Reconciliation of GAAP versus Non-GAAP Financial Results” attached to this press release.

Constant Currency Sales Growth

Constant currency sales growth is a non-GAAP financial measure that represents the change in sales between current and prior year periods using the exchange rate in effect during the applicable prior year period. A reconciliation of constant currency to GAAP sales has been provided in Table C “Sales by Geography and Non-GAAP Reconciliation of Constant Currency Sales Growth” attached to this press release.

Conference Call

The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at https://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI99b384cce5da4b33b55d2905f84b8b26) and you will be provided with dial-in details, including a personal pin.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is headquartered in San Diego, California. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the U.S. and/or other countries.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s products; products marketed and sold or under development by competitors; foreign currency exchange rates; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies and going direct in certain markets; changes in reimbursement rates or insurance coverage for the Company’s products; the success of the Company’s sales models and strategies, including the Company’s pay-as-you-go pharmacy channel reimbursement model; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process in the U.S. and internationally for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors except as required by law.

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Table A

(in thousands)

(unaudited)

September 30,

December 31,

2026

2025

Assets

Current assets:

Cash, cash equivalents and short-term investments

$

443,082

$

292,666

Accounts receivable, net

180,022

165,491

Inventories

143,121

128,769

Other current assets

54,499

31,217

Total current assets

820,724

618,143

Property and equipment, net

85,141

83,580

Operating lease right-of-use assets

98,002

96,172

Equity method investment

125,538

60,351

Other long-term assets

30,089

22,866

Total assets

$

1,159,494

$

881,112

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable, accrued expenses and employee-related liabilities

$

156,510

$

138,488

Operating lease liabilities

20,381

19,472

Deferred revenue

8,325

9,527

Other current liabilities

70,859

75,237

Total current liabilities

256,075

242,724

Convertible senior notes, net - long-term

603,388

310,036

Operating lease liabilities - long-term

112,774

114,967

Deferred revenue - long-term

7,595

8,474

Other long-term liabilities

44,575

49,741

Total liabilities

1,024,407

725,942

Total stockholders’ equity

135,087

155,170

Total liabilities and stockholders’ equity

$

1,159,494

$

881,112

TANDEM DIABETES CARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Table B

(in thousands, except per share data)

(Unaudited)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2026

2025

2026

2025

Sales

$

283,690

$

249,253

$

785,471

$

724,353

Cost of sales

123,268

114,961

343,481

345,799

Gross profit

160,422

134,292

441,990

378,554

Operating expenses:

Selling, general and administrative

113,945

108,440

333,774

331,889

Research and development

48,846

48,715

141,811

147,048

Acquired in-process research and development expenses

—

—

—

75,217

Litigation and settlement expense

—

—

—

19,951

Total operating expenses

162,791

157,155

475,585

574,105

Operating loss

(2,369

)

(22,863

)

(33,595

)

(195,551

)

Total other income (expense), net

(5,324

)

(2,280

)

(14,633

)

(9,403

)

Loss before income taxes

(7,693

)

(25,143

)

(48,228

)

(204,954

)

Income tax expense (benefit)

(608

)

(3,978

)

418

(833

)

Net loss

$

(7,085

)

$

(21,165

)

$

(48,646

)

$

(204,121

)

Net loss per share - basic and diluted

$

(0.10

)

$

(0.31

)

$

(0.70

)

$

(3.04

)

Weighted average shares used to compute basic and diluted net loss per share

69,650

67,652

69,024

67,040

TANDEM DIABETES CARE, INC.

SALES BY GEOGRAPHY AND NON-GAAP RECONCILIATION OF CONSTANT CURRENCY SALES GROWTH

Table C

(Unaudited)

($'s in thousands)

Three Months Ended
September 30,

2026

2025

% Change

Currency Impact

% Change Constant Currency

United States:

Pump

$

83,381

$

84,785

(2

)%

Supplies and other

107,664

90,846

19

%

Total Sales in the United States

$

191,045

$

175,631

9

%

—

%

9

%

International:

Pump

$

31,575

$

25,329

25

%

Supplies and other

61,070

48,293

26

%

Total International Sales

$

92,645

$

73,622

26

%

(1

)%

27

%

Total Worldwide Sales

$

283,690

$

249,253

14

%

—

%

14

%

($'s in thousands)

Nine Months Ended
September 30,

2026

2025

% Change

Currency Impact

% Change Constant Currency

United States:

Pump

$

244,324

$

242,393

1

%

Supplies and other

286,856

254,079

13

%

Total Sales in the United States

$

531,180

$

496,472

7

%

—

%

7

%

International:

Pump

$

95,710

$

81,683

17

%

Supplies and other

158,581

146,198

8

%

Total International Sales

$

254,291

$

227,881

12

%

3

%

9

%

Total Worldwide Sales

$

785,471

$

724,353

8

%

1

%

7

%

TANDEM DIABETES CARE, INC.

RECONCILIATION OF GAAP VERSUS NON-GAAP FINANCIAL RESULTS

Table D

(Unaudited)

($'s in thousands)

Three Months Ended
September 30,

Nine Months Ended
September 30,

2026

2025

2026

2025

GAAP operating loss

$

(2,369

)

$

(22,863

)

$

(33,595

)

$

(195,551

)

Litigation and settlement expense

—

—

—

19,951

Non-recurring facility impairment and restructuring costs(1)

—

—

—

11,167

Non-GAAP operating loss

$

(2,369

)

$

(22,863

)

$

(33,595

)

$

(164,433

)

GAAP operating margin(2)

(1

)%

(9

)%

(4

)%

(27

)%

Non-GAAP operating margin(2)

(1

)%

(9

)%

(4

)%

(23

)%

GAAP net loss

$

(7,085

)

$

(21,165

)

$

(48,646

)

$

(204,121

)

Income tax expense (benefit)

(608

)

(3,978

)

418

(833

)

Interest income, interest expense and other, net

5,324

2,280

14,633

9,403

Depreciation and amortization

4,513

4,493

13,487

13,171

Litigation and settlement expense

—

—

—

19,951

Stock-based compensation expense

15,893

21,141

47,293

72,271

Non-recurring facility impairment and restructuring costs(1)

—

—

—

11,167

Adjusted EBITDA

$

18,037

$

2,771

$

27,185

$

(78,991

)

Adjusted EBITDA margin(2)

6

%

1

%

3

%

(11

)%

GAAP net loss

$

(7,085

)

$

(21,165

)

$

(48,646

)

$

(204,121

)

Litigation and settlement expense

—

—

—

19,951

Non-recurring facility impairment and restructuring costs(1)

—

—

—

11,167

Non-GAAP net loss

$

(7,085

)

$

(21,165

)

$

(48,646

)

$

(173,003

)

GAAP cash used in operating activities

$

(819

)

$

8,264

$

(24,395

)

$

(19,510

)

Less: capital expenditures

(4,687

)

(4,092

)

(15,005

)

(13,263

)

Non-GAAP free cash flow (3)

$

(5,506

)

$

4,172

$

(39,400

)

$

(32,773

)

(1)

In the first quarter of 2025, the Company recorded $11.2 million in impairment charges related to its operating lease right-of-use assets, and severance and other restructuring costs associated with the relocation of certain research and development activities.

(2)

GAAP margins, including GAAP gross margin and GAAP operating margin, and non-GAAP margins, including non-GAAP operating margin and adjusted EBITDA margin, are calculated using GAAP sales.

(3)

Free cash flow is a non-GAAP financial measure that the Company defines as cash provided by operating activities less capital expenditures.

View original source (Business Wire)Tandem Diabetes Care, Inc. on 6ix

Story so far

Earlier from Tandem Diabetes Care

Later from Tandem Diabetes Care

All Tandem Diabetes Care news releases